Jose Antonio Velarde-Ruiz Velasco

Dr. Jose Antonio Velarde-Ruiz Velasco

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Revista de Gastroenterología de México
Verified
Journal Article
Open access
RBR. Bernal-Reyes
R. Bernal-Reyes
GCG. Castro-Narro
G. Castro-Narro
RMR. Malé-Velázquez
R. Malé-Velázquez
RCR. Carmona-Sánchez
R. Carmona-Sánchez
MGM.S. González-Huezo
M.S. González-Huezo
JVJose Antonio Velarde-Ruiz Velasco
Jose Antonio Velarde-Ruiz Velasco
Nonalcoholic fatty liver disease (NAFLD) affects nearly one third of the population worldwide. Mexico is one of the countries whose population has several risk factors for the disease and its prevalence could surpass 50%. If immediate action is not taken to counteract what is now considered a national health problem, the medium-term panorama will be very bleak. This serious situation prompted the Asociación Mexicana de Gastroenterología and the Asociación Mexicana de Hepatología to produce the Mexican Consensus on Fatty Liver Disease. It is an up-to-date and detailed review of the epidemiology, pathophysiology, clinical forms, diagnosis, and treatment of the disease, whose aim is to provide the Mexican physician with a useful tool for the prevention and management of nonalcoholic fatty liver disease.

10 April 2025 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
BPBryan A. Priego-Parra
Bryan A. Priego-Parra
RGRocio Gallego-Duran
Rocio Gallego-Duran
BRBerenice Román
Berenice Román
JVJose Antonio Velarde-Ruiz Velasco
Jose Antonio Velarde-Ruiz Velasco
MRManuel Romero-Gómez
Manuel Romero-Gómez
Jordi Gracia-SanchoJordi Gracia-Sancho
Jordi Gracia-Sancho

1 October 2019 in Revista de Gastroenterología de México
Verified
Journal Article
Open access
JVJose Antonio Velarde-Ruiz Velasco
Jose Antonio Velarde-Ruiz Velasco
EGE.S. García-Jiménez
E.S. García-Jiménez
KGK.R. García-Zermeño
K.R. García-Zermeño
EME.C. Morel-Cerda
E.C. Morel-Cerda
JAJ.M. Aldana-Ledesma
J.M. Aldana-Ledesma
RCR. Contreras-Omaña
R. Contreras-Omaña
Non-alcoholic fatty liver disease (NAFLD) is currently one of the main causes of chronic liver disease in Western countries, with a 25% prevalence reported in the general population worldwide. Visceral adiposity and liver fat promote a state of systemic inflammation, predisposing individuals with NAFLD to the extrahepatic pathologies of cardiovascular disease (the most common cause of death in patients with NAFLD), diabetes mellitus, chronic kidney disease, hypothyroidism, polycystic ovary syndrome, obstructive sleep apnea, and an increased risk for presenting with gastrointestinal and extraintestinal neoplasias. Different mechanisms between NAFLD and its association with extrahepatic diseases have been reported, and lipotoxicity is the main cause of inflammatory pathway activation that results in extrahepatic tissue damage.

2 October 2024 in Revista de Gastroenterología de México
Verified
Journal Article
Open access
JBJ.R. Barrientos-Ávalos
J.R. Barrientos-Ávalos
EME.C. Morel-Cerda
E.C. Morel-Cerda
FFF.A. Félix-Téllez
F.A. Félix-Téllez
BVB.E. Vidrio-Huerta
B.E. Vidrio-Huerta
AAA.R. Aceves-Ayala
A.R. Aceves-Ayala
JVJose Antonio Velarde-Ruiz Velasco
Jose Antonio Velarde-Ruiz Velasco

22 June 2018 in Revista de Gastroenterología de México
Verified
Journal Article
Open access
PDF file
FBF.J. Bosques-Padilla
F.J. Bosques-Padilla
JRJ.M. Remes-Troche
J.M. Remes-Troche
MGM.S. González-Huezo
M.S. González-Huezo
GPG. Pérez-Pérez
G. Pérez-Pérez
JTJ. Torres-López
J. Torres-López
JVJose Antonio Velarde-Ruiz Velasco
Jose Antonio Velarde-Ruiz Velasco
Desde el último consenso mexicano para el diagnóstico y tratamiento de la infección por Helicobacter pylori (H. pylori) en el 2007, han existido avances importantes al respecto. Por tal motivo, la Asociación Mexicana de Gastroenterología convocó a 20 expertos para la realización del «IV consenso mexicano sobre H. pylori». Durante febrero y junio del 2017 se organizaron 4 mesas de trabajo, una revisión de la literatura y 3 rondas de votaciones donde se establecieron 32 enunciados para discusión y consenso. Dentro de las recomendaciones se destaca el reconocer a México como un país con riesgo de cáncer gástrico bajo a intermedio a pesar de la alta prevalencia de infección por H. pylori. Se corrobora que enfermedad ulcerosa péptica, presencia de lesiones premalignas, antecedentes de cáncer gástrico y linfoma asociado a la mucosa deben considerarse indicaciones claras para erradicación. La relación del H. pylori con los síntomas dispépticos sigue siendo controversial. La triple terapia de erradicación con amoxicilina, claritromicina y un inhibidor de la bomba de protones ya no debe ser considerada la primera línea de tratamiento. En su lugar, se proponen 2 opciones: la terapia cuádruple con bismuto (inhibidor de la bomba de protones, subcitrato de bismuto, tetraciclina y metronidazol) y la terapia cuádruple sin bismuto (inhibidor de la bomba de protones, amoxicilina, claritromicina y metronidazol). Se establece la necesidad de la realización de sensibilidad antimicrobiana ante la falla a 2 tratamientos de erradicación. Finalmente, se proponen campañas de educación respecto al diagnóstico y tratamiento del H. pylori para médicos de primer contacto y población general. Important advances have been made since the last Mexican consensus on the diagnosis and treatment of Helicobacter pylori (H. pylori) infection was published in 2007. Therefore, the Asociación Mexicana de Gastroenterología summoned 20 experts to produce “The Fourth Mexican Consensus on Helicobacter pylori”. From February to June 2017, 4 working groups were organized, a literature review was performed, and 3 voting rounds were carried out, resulting in the formulation of 32 statements for discussion and consensus. From the ensuing recommendations, it was striking that Mexico is a country with an intermediate-to-low risk for gastric cancer, despite having a high prevalence of H. pylori infection. It was also corroborated that peptic ulcer disease, premalignant lesions, and histories of gastric cancer and mucosa-associated lymphoid tissue lymphoma should be considered clear indications for eradication. The relation of H. pylori to dyspeptic symptoms continues to be controversial. Eradication triple therapy with amoxicillin, clarithromycin, and a proton pump inhibitor should no longer be considered first-line treatment, with the following 2 options proposed to take its place: quadruple therapy with bismuth (proton pump inhibitor, bismuth subcitrate, tetracycline, and metronidazole) and quadruple therapy without bismuth (proton pump inhibitor, amoxicillin, clarithromycin, and metronidazole). The need for antimicrobial sensitivity testing when 2 eradication treatments have failed was also established. Finally, the promotion of educational campaigns on the diagnosis and treatment of H. pylori for both primary care physicians and the general population were proposed.

1 April 2019 in Revista de Gastroenterología de México (English Edition)
Verified
Journal Article
Open access
PDF file
AAAna Teresa Abreu
Ana Teresa Abreu
JVJose Antonio Velarde-Ruiz Velasco
Jose Antonio Velarde-Ruiz Velasco
MZM.R. Zavala-Solares
M.R. Zavala-Solares
JRJose Maria Remes-Troche
Jose Maria Remes-Troche
RCR.I. Carmona-Sánchez
R.I. Carmona-Sánchez
SJS.A. Lazo-De la Vega Jasso
S.A. Lazo-De la Vega Jasso
In recent decades, Clostridium difficile infection (CDI) has become a worldwide health problem. Mexico is no exception, and therefore the Asociación Mexicana de Gastroenterología brought together a multidisciplinary group (gastroenterologists, endoscopists, internists, infectious disease specialists, and microbiologists) to carry out the “Consensus on the prevention, diagnosis, and treatment of Clostridium difficile infection”, establishing useful recommendations (in relation to the adult population) for the medical community. Said recommendations are presented herein. Among them, it was recognized that CDI should be suspected in subjects with diarrhea that have a history of antibiotic and/or immunosuppressant use, but that it can also be a community-acquired infection. A 2-step diagnostic algorithm was proposed, in which a highly sensitive test, such as glutamate dehydrogenase (GDH), is first utilized, and if positive, confirmed by the detection of toxins through immunoassay or nucleic acid detection tests. Another recommendation was that CDI based on clinical evaluation be categorized as mild-moderate, severe, and complicated severe, given that such a classification enables better therapeutic decisions to be made. In mild-moderate CDI, oral vancomycin is the medication of choice, and metronidazole is recommended as an alternative treatment. In addition, fecal microbiota transplantation was recognized as an efficacious option in patients with recurrence or in the more severe cases of infection, and surgery should be reserved for patients with severe colitis (toxic megacolon), in whom all medical treatment has failed. La infección por Clostridium difficile (ICD) en las últimas décadas se ha convertido en un problema de salud mundial. Nuestro país no es la excepción, y por ello la Asociación Mexicana de Gastroenterología reunió a un grupo multidisciplinario (gastroenterólogos, endoscopistas, internistas, infectólogos y microbiólogos), para que realizaran el «Consenso sobre prevención, diagnóstico y tratamiento de la infección por Clostridium difficile» y se establecieran recomendaciones (dirigidas a población adulta) de utilidad para la comunidad médica. Las recomendaciones emitidas se presentan en este documento. Se reconoce que la ICD debe sospecharse en sujetos con diarrea con antecedente de uso de antibióticos y/o inmunosupresión, pero que también puede adquirirse en la comunidad. Se propone seguir un algoritmo de dos pasos para el diagnóstico, utilizando una primera prueba de alta sensibilidad como la glutamato deshidrogenasa (GDH) y, en caso de resultado positivo, se debe confirmar mediante detección de toxinas por técnica de inmunoensayo o con pruebas de detección de ácidos nucleicos. Se recomienda categorizar la ICD con base en la evaluación clínica en leve-moderada, grave o grave complicada, ya que esto permite una mejor decisión terapéutica. En la ICD leve-moderada la vancomicina oral es el medicamento de elección, y se recomienda usar metronidazol como tratamiento alternativo. El trasplante de microbiota fecal se reconoce como una opción eficaz ante las recurrencias o los casos más graves, y la cirugía debe reservarse a pacientes con colitis grave (megacolon tóxico) que han fallado a todo tratamiento médico.